By Dean Seal
South Korean vaccine company SK Bioscience said it has prevailed in a lawsuit brought by Pfizer that accused it of infringing on the patent for the drugmaker's Prevnar 13 vaccine.
The Supreme Court of Korea has ruled that the individual conjugates comprising SK Bioscience's 13-valent pneumococcal conjugate vaccine, or PCV13, don't fall within the scope of Pfizer's patent claims, SK Bioscience said Wednesday.
The high court also confirmed that the production and supply of PCV13 finished products for research purposes don't constitute patent infringement, the company said.
A representative for Pfizer didn't immediately respond to a request for comment.
Pfizer claimed in its 2020 suit that SK Bioscience's export of PCV13 individual conjugate bulk substances and research-use finished products to Russia infringed on the composition patent for Prevnar 13, its pneumococcal vaccine.
Now that the ruling has come down, SK Bioscience said it intends to start exporting individual components of PCV13 to countries with high vaccine demand, including nations in Southeast Asia and Latin America.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
May 21, 2025 08:39 ET (12:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.